terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 3, 2026

Stocks Settle Lower on Iran War Anxiety

View original at nasdaq.com
Stocks Settle Lower on Iran War Anxiety The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.94%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.83%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.09%…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Real-time risk premium for crude oil is $18/bbl, corresponding to impact of six-week full halt to tanker traffic in Strait of Hormuz

    80% confidence
  • Inflation has been above Fed's objective for nearly five years, so no room to be complacent

    80% confidence
  • Iran will set fire to any ship attempting to pass through Strait of Hormuz

    80% confidence
  • Additional Fed interest rate cuts will be warranted if inflation slows further once most of tariff impact has passed

    80% confidence
  • Combat operations against Iran could last for weeks until all objectives completed

    80% confidence
  • S&P 500 earnings growth expected to climb 8.4% in Q4, marking tenth consecutive quarter of year-over-year growth

    80% confidence
  • Excluding Magnificent Seven megacap tech stocks, Q4 earnings expected to increase 4.6%

    80% confidence
  • Ordered US Development Finance Corporation to provide political risk insurance and guarantees for maritime trade through Gulf at reasonable price

    80% confidence
  • US Navy will begin escorting tankers through Strait of Hormuz as soon as possible if necessary

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com